




RENAL CELL CARCINOMA (RCC)

Classic triad <15%: palpable mass, hematuria, pain. **20-30% METASTATIC** at presentation. **95% sporadic/5% familial**(all AD)
Most common RCC metastasis sites: lung-bone-liver **Most common mtx at kidney:** lung carcinomas
PARANEOPLASTIC SYNDROMES 1/3: not necessary metastatic: **HYPERCALCEMIA, STAUFFER SYNDROME** (hepatic dysfunction with no mtx),
POLYCYTEMIA, ANEMIA, HYPERTENSION.

PROGNOSIS: worse to better: CLEAR CELL- PAPILLARY 2- PAPILLARY 1- CROMOPHOBE

	ORIGIN	GENES	CT	OTHERS/SYNDROMES
CLEAR CELL 75-80%	Proximal tubules	VHL gene 3p		Hypervascular, heterogeneous, contrast enhancement, necrosis, hemorrhage, cystic degeneration. VHL: CLEAR CELL CARCINOMA BILAT. MULTIFOCAL +PHEOCHROMOCYTOMAS + retinal angioma + hemangioblastomas nervous system
PAPILLARY 10-15%	Proximal tubules	Type 1: cMet7q31 Type 2: fumarate hydratase 1q		Hypovascular with peripheral enhancement Type 1: basophilic Type 2: eosinophilic (more aggressive) MOST COMMON RCC IN KIDS HEREDITARY PAPILLARY RCC:TYPE 1:Trisomy7-17 HEREDITARY LEIOMYOMATOSIS AND RCC: TYPE 2: Cutaneous, uterine leiomyomata
CROMOPHOBE 5%	Distal tubules	Gene of folliculin 17p		Hypovascular, homogeneous enhancement BIRT-HOGG-DUBE SYNDROME: CROMOPHOBIC RCC + ONCOCYTOMAS + cutaneous fibromas + pulmonary cysts

OTHER TUMORS

ONCOCYTOMA (benign):

5% Renal tumors

Homogeneous hypervascular.
Central scar



Radiograp: similar RCC: **SURGERY**

Distal tubules (histol. similar chromophobe RCC)

BIRT-HOGG- DUBE SYNDROME

ANGIOMYOLIPOMA (benign): **FAT-10 UH**

-Female predilection

-Epithelioid, paucity of fat: 1/3 malignant

-**Treatment (surgery/embolization):>4cm**


(consider early treatment in female desiring pregnancy)

WUNDERLICH SYNDROME: massive retrop. bleeding

TUBEROUS SCLEROSIS: 20-25% patients with AML.

+pheochromocytomas, sebaceous adenoma, seizures, mental retardation.

EVEROLIMUS (Mtor-inh)



CYSTS BOSNIAK

CLASSIFICATION	CT	% MALIGNANCY	MANAGEMENT
I	Benign simple cyst (0-20 HU), thin walls.	~0%	Treatment in symptomatic. No follow-up
II	Thin septa, fine calcification, <3cm	<3%	Treatment in symptomatic. No follow-up
III	Multiple thin septa and calcifications, >3cm	5-10%	PERIODIC FOLLOW-UP (CT/MRI/US)
IV	Thick or irregular septa, important calcifications. Contrast enhancement	~50%	SURGERY
IV	Clearly malignant. Thick walls, nodular areas, heterogeneous. Enhance with contrast.	75-90%	SURGERY